With new study results, Johnson & Johnson can tout Tremfya's efficacy across all skin tones
Fierce Pharma
OCTOBER 19, 2023
The first biologic to win approval to treat moderate to severe psoriasis was Astellas’ now-discontinued Amevive (alefacept) in 2003, paving the way for significant progress in the disease space. | The VISIBLE trial is the first large-scale psoriasis study in only people of color, J&J said.
Let's personalize your content